The Codon Capital Team
|
Mitchell Mutz, PhD, is an accomplished biotech serial entrepreneur, venture investor, and inventor. Prior to joining Codon, Mitchell was Senior Investment Director at the Roche Venture Fund, a $500M Swiss corporate venture fund which invests for financial return. His portfolio included Enliven Therapeutics, Fabric Genomics, Good Therapeutics, Jasper Therapeutics, Kumquat Biosciences, lino Biotechnology, Pandion Therapeutics (NASDAQ:PAND), Purigen Biosystems, Stratos Genomics (acquired by Roche) and BlueLight Therapeutics. He also collaborated on three new company spinouts from Roche which attracted over $50M in external venture investment. Before that he served as a venture partner at Codon Capital.
Previously, Mitchell was a co-founder, president, chief scientific officer, and board member of Amplyx Pharmaceuticals, Inc., a biotherapeutics company and Stanford University spinout. Mitchell led the company's R&D efforts, team building, as well as financing and in-licensing strategy and helped grow the company from early preclinical discovery to the clinical stage. Amplyx has attracted over $140M in venture financing as well as over $11M in non-dilutive funding from the NIH. Amplyx had a successful Phase 2 clinical trial readout in July 2020 and plans to commence Phase 3 studies in 2021. Mitchell was also on the founding team and the Principal Scientist of Labcyte, a tools company that he helped grow from a garage-based start-up to profitability. Mitchell was responsible for discovering and and developing biotechnology applications for Labcyte's novel acoustic drop ejection technology. Labcyte employs over 250 people worldwide, attracted $85M in venture financing, and was acquired by Beckman Coulter Life Sciences for $308M. Mitchell earned a Ph.D. in chemistry from the University of Rochester, a diploma in orchestral studies from the University of London, and a B.A. in chemistry with high honors from Oberlin College. He also spent one year studying towards a PhD in the Department of Cellular and Developmental Biology at Harvard University with Karl Handelsman. Mitchell is also an inventor on 36 issued patents. More: Mutz's LinkedIn |
“The value creation should be obvious. There are alot of investments that are attractive when you evaluate them on a spreadsheet, but if you need a spreadsheet to know an investment is a value it's not for Codon Capital.
- Karl D.Handelsman, Codon Capital |